Effect of empagliflozin on all-cause hospitalization in EMPA-KIDNEY

被引：0
|
作者：
Uster, Anastasia [1 ]
Desai, Nihar [2 ]
Navaneethan, Sankar [3 ]
Pfarr, Egon [1 ]
Mazo, Anna Rita [1 ]
机构：
[1] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[2] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA
[3] Baylor Coll Med, Nephrol Sect, Dept Med, Selzman Inst Kidney Hlth, Houston, TX USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2024年 / 153卷
关键词：
D O I：
10.1016/j.metabol.2024.155857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0047
引用
收藏
页数：2
相关论文
共 50 条
  • [21] IMPACT OF POLYPHARMACY ON ALL-CAUSE MORTALITY, ALL-CAUSE HOSPITALIZATION AND CARDIOVASCULAR EVENTS IN INITIAL JAPANESE HEMODIALYSIS PATIENTS
    Toida, Tatsunori
    Toida, Reiko
    Ebihara, Shou
    Uezono, Shigehiro
    Komatsu, Hiroyuki
    Sato, Yuji
    Fujimoto, Shouichi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1831 - 1831
  • [22] USE OF ANTICHOLINERGIC MEDICATIONS AND RISK OF ALL-CAUSE HOSPITALIZATION IN THE ELDERLY
    Chatterjee, S.
    Carnahan, R. M.
    Chen, H.
    Holmes, H. M.
    Johnson, M. L.
    Aparasu, R. R.
    VALUE IN HEALTH, 2014, 17 (03) : A155 - A155
  • [23] Clinical (symptomatic) fractures are predictors of all-cause hospitalization.
    Thompson, DE
    Cummings, S
    Black, D
    Capizzi, T
    Ensrud, K
    Yates, AJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : 167 - 167
  • [24] MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL
    Jardine, M.
    Wanner, C.
    Nangaku, M.
    Kraus, B.
    Zinman, B.
    Mattheus, M.
    Hantel, S.
    Schumacher, M.
    Ohneberg, K.
    Schmoor, C.
    Inzucchi, S. E.
    NEPHROLOGY, 2021, 26 : 19 - 19
  • [25] In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 mo
    Keppel, Stormy
    Borzak, Steven
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (07) : JC74 - JC74
  • [26] Association Between Exposure to Evidence-Based Heart Failure Drug Treatment and All-Cause Hospitalization and All-Cause Mortality
    Moisan, Jocelyne
    Girouard, Catherine
    Perez, Norma
    Demers, Eric
    Gregoire, Jean-Pierre
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 202 - 203
  • [27] Effect of Raloxifene on All-cause Mortality
    Grady, Deborah
    Cauley, Jane A.
    Stock, John L.
    Cox, David A.
    Mitlak, Bruce H.
    Song, Jingli
    Cummings, Steven R.
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (05): : 469.e1 - 469.e7
  • [28] Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
    Scheen, Andre J.
    DIABETES & METABOLISM, 2016, 42 (02) : 71 - 76
  • [29] Glycemic Control and Risk of Cardiovascular Disease Hospitalization and All-Cause Mortality
    Nichols, Gregory A.
    Joshua-Gotlib, Sandra
    Parasuraman, Shreekant
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (02) : 121 - 127
  • [30] Modifiable risk factors for all-cause hospitalization in obstructive lung disease
    Beijers, Rosanne
    Van den Borst, Bram
    Newman, Anne
    Yende, Sachin
    Kritchevsky, Stephen
    Cassano, Patricia
    Harris, Tamara
    Schols, Annemie
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
12345